Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers

Annals of Thoracic and Cardiovascular Surgery

Volumn 15, Issue 5, 2009, Pages 304-310

  Nakamura, Haruhiko ^b   Hirata, Takeshi ^a   Kitamura, Hajime ^a   Nishikawa, Junichi ^a  

^a International University of Health and Welfare   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ki 67; Luorodeoxyglucose; Non small cell lung cancer; P53; Positron emission tomography

Indexed keywords

CELL CYCLE PROTEIN; CYCLINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; SCINTISCANNING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72049103162     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Duhaylongsod F, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52.
2. de Geus-Oei L, van Krieken JH, Aliredjo R, Krabbe PF, Frielink C, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87.
3. Kieninger A, Welsh R, Bendick P, Zelenock G, Chmielewski GW. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg 2006;191:433-6.
4. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected nonsmall cell lung cancer. J Nucl Med 2002;43:39-45.
5. Borst GR, Belderbos JS, Boellaard R, Comans EF, de Jaeger K, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41.
6. Davies A, Tan C, Paschalides C, Barrington SF, O'Doherty M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007;55:75-8.
7. 18 F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-73.
8. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, et al. Positron emission tomography in nonsmall-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
9. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 2006;54:41-9.
10. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-67.
11. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 1993;29A:363-5.
12. Matturri L, Lavezzi AM, Grignani F, Salomoni G, Roviaro GC. The prognostic value of cell proliferation in non-small cell lung cancer assessed with tritiated thymidine and anti-PCNA antibodies. Eur J Cancer 1994;30A:1397-8.
13. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
14. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9.
15. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-20.
16. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40.
17. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-503.
18. Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, et al. Proliferating cell nuclear antigen may be superior to argyrophillic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol 1995;4: 83-9.
19. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
20. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
21. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
22. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44.
23. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
24. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 2006;36:403-9.
25. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92.
26. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369-79.
27. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, et al. Evaluation of thoracic tumors with 18F-f luorot hym idine a nd 18F-f luorodeoxyglucose-posit r o n emission tomography. Chest 2006;129:393-401.
28. Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, et al. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med 2003;17:189-96.
29. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehülsing M, et al. Prognostic significance of Ki-67 (MIB-1), PCNA and p53 in cancer of oropharynx and oral cavity. Oral Oncol 1999;35:583-9.
30. Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, et al. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006;35:1005-10.
31. Scott RJ, Hall PA, Haldane JS, van Noorden S, Price Y, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991;165:173-8.
32. Nakamura H, Saji H, Ogata A, Saijo T, Okada S, et al. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge rese ction. Lung Cancer 2004;44:61-8.
33. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, et al. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, nonsmall-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 1996;111:1125-34.